Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

The Latest Breaking News from Nasdaq

Executives Buy Around $141M Of 4 Stocks

Although Dow Jones futures traded higher this morning on Tuesday, there were a few notable insider trades.

Benzinga

The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves

Here's a roundup of top developments in the biotech space over the last 24 hours:

Benzinga

Turning Point Therapeutics Gets FDA Breakthrough Therapy designation For Repotrectinib

Turning Point Therapeutics, Inc. (NASDAQ: TPTX) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for its lead drug candidate Repotrectinib in Patients With One Prior ROS1 Tyrosine Kinase Inhibitor and no Prior Chemotherapy.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Reading Intl: Q1 Earnings Insights

Reading Intl (NASDAQ:RDI) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:30 AM. Here's what investors need to know about the announcement. Earnings Reading Intl missed estimated earnings by 59.09%, reporting an EPS of $-0.7 versus an estimate of $-0.44.

Benzinga

Where BioNTech Stands With Analysts

Within the last quarter, BioNTech (NASDAQ:BNTX) has observed the following analyst ratings:

Benzinga

Analyst Ratings for Heska

Over the past 3 months, 4 analysts have published their opinion on Heska (NASDAQ:HSKA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

What 13 Analyst Ratings Have To Say About Upstart Hldgs

Analysts have provided the following ratings for Upstart Hldgs (NASDAQ:UPST) within the last quarter:

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Analyst Ratings for Victory Capital Holdings

Victory Capital Holdings (NASDAQ:VCTR) has observed the following analyst ratings within the last quarter:

Benzinga

How Is The Market Feeling About Tesla?

Tesla's (NASDAQ:TSLA) short percent of float has fallen 3.32% since its last report. The company recently reported that it has 24.55 million shares sold short, which is 2.91% of all regular shares that are available for trading.

Benzinga

Dream Finders Homes: Q1 Earnings Insights

Dream Finders Homes (NASDAQ:DFH) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Achilles Therapeutics: Q1 Earnings Insights

Achilles Therapeutics (NASDAQ:ACHL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Analyst Ratings for CarGurus

Within the last quarter, CarGurus (NASDAQ:CARG) has observed the following analyst ratings:

Benzinga

Expert Ratings for Tesla

Over the past 3 months, 14 analysts have published their opinion on Tesla (NASDAQ:TSLA) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Expert Ratings for Viatris

Analysts have provided the following ratings for Viatris (NASDAQ:VTRS) within the last quarter:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap: Aclaris Therapeutics Q1 Earnings

Aclaris Therapeutics (NASDAQ:ACRS) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

PMV Pharma: Q1 Earnings Insights

PMV Pharma (NASDAQ:PMVP) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:30 AM. Here's what investors need to know about the announcement.

Benzinga

Phathom Pharmaceuticals: Q1 Earnings Insights

Phathom Pharmaceuticals (NASDAQ:PHAT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

Ovid Therapeutics: Q1 Earnings Insights

Ovid Therapeutics (NASDAQ:OVID) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap: Katapult Holdings Q1 Earnings

Katapult Holdings (NASDAQ:KPLT) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Vertex Q1 Earnings

Vertex (NASDAQ:VERX) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Village Farms Intl: Q1 Earnings Insights

Village Farms Intl (NASDAQ:VFF) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: PowerFleet Q1 Earnings

PowerFleet (NASDAQ:PWFL) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Recap: Lyra Therapeutics Q1 Earnings

Lyra Therapeutics (NASDAQ:LYRA) reported its Q1 earnings results on Tuesday, May 10, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Benzinga

Nuwellis: Q1 Earnings Insights

Nuwellis (NASDAQ:NUWE) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Benzinga

L.B. Foster: Q1 Earnings Insights

L.B. Foster (NASDAQ:FSTR) reported its Q1 earnings results on Tuesday, May 10, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

1 … 590 591 592 593

People

Dara Khosrowshahi

130 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.